- £81.91bn
- £95.80bn
- £32.67bn
REG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Total Voting Rights
AnnouncementREG - GlaxoSmithKline PLC - GSK’s daprodustat gains first regulatory approval
AnnouncementREG - GlaxoSmithKline PLC - FDA Advisory Committee review belantamab mafodotin
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Total Voting Rights
AnnouncementREG - GlaxoSmithKline PLC - Second Price Monitoring Extn
AnnouncementREG - GlaxoSmithKline PLC - Price Monitoring Extension
AnnouncementREG - GlaxoSmithKline PLC - Block listing Interim Review
AnnouncementREG - GlaxoSmithKline PLC - Holding(s) in Company
AnnouncementREG - GlaxoSmithKline PLC - ViiV PrEP jab shows high efficacy over daily pill
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSK Capital PLC GlaxoSmithKline PLC - Publication of Final Terms
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
Announcement